Original Query: ALL
Previous Study | Return to List | Next Study

Azacitidine (AZA) in Minimal Residual Disease (MRD) Chronic Myeloid Leukemia (CML)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01460498
Recruitment Status : Active, not recruiting
First Posted : October 27, 2011
Last Update Posted : October 23, 2017
Celgene Corporation
Information provided by (Responsible Party):
M.D. Anderson Cancer Center

No Study Results Posted on for this Study
  Recruitment Status : Active, not recruiting
  Estimated Primary Completion Date : August 2019
  Estimated Study Completion Date : August 2019